Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.

Phase 3 results support QTORIN rapamycin as a potential first targeted therapy for patients with debilitating microcystic lymphatic malformations.

Pegzilarginase is an enzyme replacement therapy that provides an exogenous source of the deficient human arginase 1 enzyme to reduce blood arginine levels.

Clinical guideline developed by the American Heart Association and the American College of Cardiology.

In the phase 2/3 MUSCLE trial, ulviprubart failed to reach statistical significance for functional and strength endpoints in inclusion body myositis.

HealthDay News — A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it. The test, called Galleri, failed to lower the number of ...

HealthDay News — In guidelines issued by the American Society of Hematology and published online February 11 in Blood Advances, recommendations are presented for frontline management of acute ...

HealthDay News — People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior ischemic optic neuropathy (NAION) vs those starting sodium-glucose ...

The 4-dose KwikPen device supports weight reduction in patients with obesity or overweight with weight-related conditions.

Seralutinib shows potential benefit in high-risk pulmonary arterial hypertension subgroups; safety data note cough and liver enzyme elevations as risks.

The device is administered as a swallowable capsule that is filled with liquid by a physician and naturally leaves the body after approximately 4 months.

The REDEFINE 4 trial evaluated weight loss outcomes for CagriSema vs tirzepatide in over 800 adults with obesity through week 84.